DMRA trades 93.6% below Wall Street's consensus target of $43.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DMRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Damora Therapeutics, Inc. (DMRA) has a Wall Street consensus price target of $43.67, based on estimates from 5 covering analysts. With the stock currently trading at $22.56, this represents a potential upside of +93.6%. The company has a market capitalization of $369M.
Analyst price targets range from a low of $40.00 to a high of $46.00, representing a 14% spread in expectations. The median target of $45.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, DMRA trades at a trailing P/E of -1.3x. Analysts expect EPS to grow +94.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GALTGalectin Therapeutics Inc. | $192M | $2.91 | $11.00 | +278.0% | Buy | — | 11 |
IMVTImmunovant, Inc. | $6.9B | $33.21 | $40.00 | +20.4% | Buy | — | 23 |
TGTXTG Therapeutics, Inc. | $9.6B | $62.71 | $80.50 | +28.4% | Buy | 62.7x | 13 |
PRTAProthena Corporation plc | $432M | $8.26 | $30.00 | +263.2% | Buy | 69.6x | 28 |
ARQTArcutis Biotherapeutics, Inc. | $3.4B | $27.33 | $41.80 | +52.9% | Buy | 66.3x | 12 |
IDYAIDEAYA Biosciences, Inc. | $2.4B | $27.40 | $53.20 | +94.2% | Buy | — | 26 |
KYMRKymera Therapeutics, Inc. | $10.0B | $121.52 | $141.53 | +16.5% | Buy | — | 27 |
RVMDRevolution Medicines, Inc. | $34.6B | $162.69 | $253.47 | +55.8% | Buy | — | 25 |
AGENAgenus Inc. | $259M | $6.21 | $25.00 | +302.6% | Buy | 23.2x | 12 |
HALOHalozyme Therapeutics, Inc. | $11.4B | $95.97 | $110.00 | +14.6% | Buy | 11.1x | 27 |
Quick answers to the most common questions about buying DMRA stock.
The consensus Wall Street price target for DMRA is $43.67, representing 93.6% upside from the current price of $22.56. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DMRA has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $43.67 implies 93.6% upside from current levels.
DMRA's current price is $22.56 with a consensus target of $43.67 (93.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $46 for DMRA, while the most conservative target is $40. The consensus of $43.67 represents the median expectation. These targets typically reflect 12-month expectations.
DMRA is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DMRA stock forecast based on 5 Wall Street analysts shows a consensus price target of $43.67, with estimates ranging from $40 (bear case) to $46 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DMRA, with a "Buy" consensus rating and $43.67 price target (93.6% upside). 3 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DMRA analyst price targets range from $40 to $46, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $43.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.